Shattuck Labs: Priced As If Risk Was Not A Part Of The Equation
Shattuck Labs is shifting its focus from oncology to autoimmune diseases following a setback in its pipeline. The company is now banking on its early-stage asset SL-325, which targets inflammatory bowel disease (IBD). Analysts express concerns over the stock's valuation and the high risks associated with the drug's approval process.
- ▪Shattuck Labs is pivoting to autoimmune diseases after a pipeline failure in oncology.
- ▪The company's new asset, SL-325, is currently in Phase 1 trials targeting IBD.
- ▪Analysts rate the stock as a Sell due to high valuation and low probability of drug approval.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4907630-shattuck-labs-priced-as-if-risk-was-not-a-part-of-the-equation"},"author":{"@type":"Person","name":"Cypriot Invests","url":"https://seekingalpha.com/author/cypriot-invests"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
